BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14

• Press Releases

  BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

  August 10, 2026

   · 

  8 min read
• 

  Pipeline

  BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication

  BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.

  August 10, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

  August 10, 2026

   · 

  6 min read
• Press Releases

  Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

  August 10, 2026

   · 

  10 min read
• Press Releases

  Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

  August 10, 2026

   · 

  3 min read
• Press Releases

  Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

  August 10, 2026

   · 

  3 min read
• Press Releases

  Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

  August 10, 2026

   · 

  7 min read
• Press Releases

  Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

  August 10, 2026

   · 

  8 min read
• Press Releases

  AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

  August 10, 2026

   · 

  7 min read
• Press Releases

  Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

  August 10, 2026

   · 

  4 min read